Bank Loans, MLPs Be...
Health Care: Drugs
ViroPharma Inc. (VPHM: NASDAQ)
$26.10 0.24 | 0.93%
05/22/13 - 04:00 PM ET
Company Cash Flow
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Cash Flow From Operating Activities | ||||
|---|---|---|---|---|
| Net Income (Loss) | 5.61M | 140.66M | 125.61M | -11.08M |
| Operating Gains/Losses | 0.00 | 0.00 | 0.00 | -9.08M |
| Extraordinary Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| (Increase) Decrease In Receivables | 4.21M | -34.86M | -2.10M | -26.00M |
| (Increase) Decrease in Inventories | -3.25M | -6.94M | -12.32M | -13.62M |
| (Increase) Decrease In Other Current Assets | 0.00 | 0.00 | 0.00 | 3.43M |
| (Decrease) Increase In Payables | 9.30M | -159.00K | 4.01M | -211.00K |
| (Decrease) Increase In Other Current Liabilities | -10.06M | 26.55M | 15.07M | -2.84M |
| (Increase) Decrease In Other Working Capital | -9.81M | 100.00K | -4.06M | 3.17M |
| Other Non-Cash Items | 22.04M | 41.18M | 19.71M | 87.63M |
| Net Cash From Continuing Operations | 43.02M | 170.73M | 193.52M | 84.78M |
| Net Cash From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Provided By Investing Activities | ||||
| Net Cash From Total Operating Activities | 43.02M | 170.73M | 193.52M | 84.78M |
| Sale of Property, Plant & Equipment | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Investing Activities | ||||
| Sale of Short-Term Investments | 162.73M | 0.00 | 0.00 | 0.00 |
| Purchases of Property, Plant & Equipment | -1.33M | -3.01M | -2.81M | -1.93M |
| Acquisitions | -92.27M | -32.04M | -13.15M | 0.00 |
| Purchases of Short-Term Investments | -107.18M | 0.00 | 0.00 | 0.00 |
| Other Cash from Investing Activities | 0.00 | -14.50M | 0.00 | 0.00 |
| Cash Provided by Financing Activities | ||||
| Net Cash From Investing Activities | -38.05M | -101.05M | -101.93M | -8.93M |
| Issuance of Debt | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Used for Financing Activities | ||||
| Issuance of Capital Stock | 11.96M | 14.69M | 3.54M | 378.00K |
| Repayment of Long-Term Debt | 0.00 | -292.00K | -1.58M | -21.15M |
| Repurchase of Capital Stock | -180.34M | -169.66M | 0.00 | 0.00 |
| Payment of Cash Dividends | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Charges, Net | 7.12M | -7.96M | 1.60M | 318.00K |
| Net Cash From Financing Activities | -161.27M | -163.21M | 3.56M | -20.45M |
| Effect of Exchange Rate Changes | 467.00K | -1.84M | -88.00K | 437.00K |
| Net Change in Cash & Cash Equivalents | -155.83M | -95.38M | 95.06M | 55.83M |
Portfolios with VPHM
- Portfolio NameUser Type
- ProJoel Greenblatt - Gotham Ca...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Userjohnnystocks
- ContributorEarnings Short Squeeze Play...
- UserGFNN Stockdiagnostics 3
- ContributorEarnings Short Squeeze Play...
- ContributorStocks At New 52-Week Highs...
- UserStocks
- ContributorEarnings Short Squeeze Play...
Latest VPHM Headlines from TheStreet
- 'Mad Money' Lightning Round: Buy More Travelers 04.18.13 | 06:04 am
- Cramer's 'Mad Money' Recap: Haves and Have-Nots 04.17.13 | 08:04 pm
- Bullish Two Hundred Day Moving Average Cross - VPHM 04.12.13 | 05:04 pm
- Cramer's 6 Stocks in 60 Seconds: TRLA LULU EOG BDX CMG VPHM (Update1) 03.27.13 | 05:03 pm
- Cramer's Top Stock Picks: WPRT VPHM TXN JDSU CSC 03.09.13 | 06:03 am
- Cramer's 'Mad Money' Recap: Next Week's Game Plan 03.08.13 | 07:03 pm
- ViroPharma Inc. Stock Downgraded (VPHM) 11.19.12 | 04:11 am
- 8 Stocks Soaring Higher With Big Volume 09.21.12 | 02:09 pm
- ViroPharma's CEO Discusses Q2 2012 Results - Earnings Call Transcript 08.10.12 | 06:08 pm
- 5 Biotech Stocks Poised for Breakouts 07.27.12 | 01:07 pm
Press Releases for VPHM
- ViroPharma To Release 2012 Fourth Quarter And Full Year Financial Results On February 27, 2013 - PR Newswire 02.22.13 | 12:02 pm
- ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences - PR Newswire 02.11.13 | 12:02 pm
- Sub-Group Analysis Of Data From Pediatric Patients With Hereditary Angioedema Published In The Journal Of Pediatrics - PR Newswire 01.16.13 | 08:01 am
- ViroPharma Provides 2013 Outlook - PR Newswire 01.07.13 | 07:01 am
- ViroPharma And Halozyme Therapeutics Announce Initiation Of Phase 2b Dose Ranging Combination Study For Subcutaneous Administration Of Cinryze® (C1 Esterase Inhibitor [human]) With Hyaluronidase (rHuPH20) - PR Newswire 12.19.12 | 07:12 am
- ViroPharma Launches Novel Campaign To Illustrate The Emotional Burden Of Hereditary Angioedema - PR Newswire 12.12.12 | 08:12 am
- ViroPharma To Participate In Two December Healthcare Investor Conferences - PR Newswire 11.29.12 | 04:11 pm
- ViroPharma's Cinryze® (C1 Esterase Inhibitor [Human]) Prophylaxis Study Showed Safety Data Of Escalating Doses In Patients With Hereditary Angioedema - PR Newswire 11.13.12 | 07:11 am
- ViroPharma To Participate In Two November Healthcare Investor Conferences - PR Newswire 11.08.12 | 02:11 pm
- Health Canada Approves New Drug Submission For Cinryze⢠(C1 Inhibitor [human]) - PR Newswire 10.22.12 | 08:10 am
Partner Headlines for VPHM
- Top Mutual Funds Still Nibbling At Ocwen Financial - Investor's Business Daily 02.04.13 | 06:02 pm
- Pertaining to Relief for ViroPharma - Analyst Blog - NASDAQ 09.25.12 | 07:09 pm
- Abbott-Astellas Collaborate - Analyst Blog - Zacks 09.13.12 | 06:09 pm
- ViroPharma Misses Zacks Estimates - Analyst Blog - Zacks 08.10.12 | 09:08 am
- VPHM Manufacturing Process Approved - Analyst Blog - Zacks 08.07.12 | 07:08 pm
- ViroPharma Receives FDA Approval of Cinryze - Benzinga 08.06.12 | 01:08 pm
- Bad News for ViroPharma - Analyst Blog - Zacks 08.03.12 | 06:08 pm
- ViroPharma's Cinryze® (C1 esterase inhibitor [human]) Open Label Prophylaxis Study Showed Up To 2.6 Years Of Effectiveness In Majority Of Subjects - Benzinga 07.27.12 | 09:07 am
- ViroPharma Initiates Phase II Study - Analyst Blog - Zacks 06.05.12 | 07:06 pm
- ViroPharma Falters, Guides Lower - Analyst Blog - Zacks 05.02.12 | 10:05 am
